Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Phase II data encourage further development of aminopeptidase N inhibitor in leukemia

Dec. 16, 2011

AVL-292 may alleviate myeloma-related bone disease

Dec. 16, 2011

New malaria vaccines tested in vivo by U.S. investigators

Dec. 16, 2011

New schistosomiasis vaccine candidate developed in Switzerland

Dec. 16, 2011

PARP inhibitor shows promise combined with temozolomide in advanced solid tumors

Dec. 16, 2011

PANORAMA 1 study evaluates panobinostat in multiple myeloma

Dec. 16, 2011

Avila Therapeutics product shows promise to treat hematological cancers

Dec. 15, 2011

Novel antimalarial is potent without inducing parasite dormancy

Dec. 15, 2011

Antitumor effects of K-560 evaluated in preclinical settings

Dec. 15, 2011

Second remissions evaluated in epratuzumab study in relapsed acute lymphoblastic leukemia

Dec. 15, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...